Here are 1-3 brief analogies for Spyre Therapeutics (SYRE):

• Like an early-stage Vertex Pharmaceuticals, but hyper-focused on developing highly effective, disease-modifying treatments for inflammatory bowel disease (IBD).
• Similar to Regeneron or Amgen, but specialized in creating next-generation antibody and oral therapies specifically for inflammatory bowel disease.
• A biotech aiming to develop the 'next-generation Humira or Entyvio' for conditions like Crohn's and ulcerative colitis, with a focus on improved efficacy and patient convenience.

• SPY001: A next-generation subcutaneous TL1A antibody being developed for the treatment of inflammatory bowel disease (IBD), designed for infrequent dosing.
• SPY002: An oral, gut-restricted α4β7 integrin inhibitor currently in preclinical development for the treatment of inflammatory bowel disease (IBD).

Spyre Therapeutics (symbol: SYRE) is a clinical-stage biotechnology company focused on the discovery and development of novel precision medicines.

As a clinical-stage company, Spyre Therapeutics does not currently have any commercial products on the market, nor does it generate revenue from product sales. Therefore, the company does not have "major customers" in the traditional sense, whether these be other companies or individual consumers.

The business model for companies at this stage involves advancing their drug candidates through preclinical and clinical development. Potential future monetization would typically come through licensing agreements, collaborations with larger pharmaceutical companies, or an outright acquisition once their pipeline assets show significant promise and progress towards regulatory approval.

null

Cameron Turtle, Chief Executive Officer

Cameron Turtle, D.Phil., is an experienced leader in building, financing, and shaping biopharma organizations from preclinical development to late-stage clinical trials and commercialization. Prior to joining Spyre Therapeutics, he served as Venture Partner at Foresite Labs and as Chief Strategy Officer of BridgeBio Pharma. Before that, he was the Chief Business Officer of Eidos Therapeutics, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for heart failure. Dr. Turtle was also a consultant at McKinsey & Company, working with pharmaceutical and medical device companies on M&A, growth strategy, clinical trial strategy, and sales force optimization. He has served as a Director for several other biotech companies, including CoA Therapeutics, Fortify Therapeutics, Dermecular Therapeutics, and Aspa Therapeutics, which suggests a pattern of involvement with companies that often receive private equity or venture capital backing. He currently serves on the board of directors of Oruka Therapeutics, Inc.

Scott Burrows, Chief Financial Officer

Scott Burrows, M.B.A., is a veteran of the biopharma industry with more than two decades of diverse experience and a proven track record in biopharmaceutical finance leadership roles spanning multiple public companies. Prior to Spyre, he served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc., where he helped lead Arcutis through a successful initial public offering (IPO), several further equity and debt financings, and the transition to a fully integrated commercial-stage company. The successful IPO and venture capital financings at Arcutis indicate experience with companies backed by significant private and public investment. Before Arcutis, Mr. Burrows was the head of international investor relations for Shire, plc. Earlier in his career, he spent 15 years at Amgen, Inc. in roles of increasing responsibility across financial planning and analysis, treasury, and investor relations. Mr. Burrows began his career at Arthur Andersen as a consultant.

Heidy King-Jones, Chief Legal Officer and Corporate Secretary

Heidy King-Jones was appointed as Chief Legal Officer and Corporate Secretary of Spyre Therapeutics effective September 1, 2023.

Sheldon Sloan, M.D., Chief Medical Officer

Sheldon Sloan, M.D., serves as the Chief Medical Officer of Spyre Therapeutics, a position he has held since 2024.

Brian Connolly, Chief Technical Officer

Brian Connolly is the Chief Technical Officer at Spyre Therapeutics.

There are two clear emerging threats for Spyre Therapeutics (SYRE):

• Pfizer's PF-07062119 (formerly RVT-3101) TL1A inhibitor: Pfizer's acquisition of Telavant in late 2023 for $7.1 billion, based on compelling Phase 2b data for this TL1A inhibitor in ulcerative colitis, represents a significant and advanced direct competitor to Spyre's lead candidate, SP-162. Given Pfizer's substantial investment and the strong clinical results reported for PF-07062119, this drug is significantly further along in development than SP-162 and, if successful in Phase 3, could establish a strong market position for TL1A inhibitors or capture substantial market share before Spyre's candidate reaches the market.
• Oral alpha4beta7 integrin inhibitors such as BridgeBio Pharma's BBT-401: While Spyre's SP-212 aims to differentiate through an extended half-life for infrequent dosing, the emergence of effective oral alpha4beta7 integrin inhibitors presents a threat. BridgeBio Pharma has reported positive Phase 2a data for its oral BBT-401 in Crohn's disease. The significant patient preference for oral administration over injections could make such a therapy highly disruptive and competitive, potentially impacting the market for injectable alpha4beta7 integrin inhibitors, regardless of their dosing frequency.

Spyre Therapeutics (SYRE) is a clinical-stage biotechnology company primarily focused on developing next-generation antibody treatments for inflammatory bowel disease (IBD) and other immune-mediated conditions. Their pipeline includes SPY001 (an anti-α4β7 integrin), SPY002 (an anti-TL1A antibody), and SPY003 (an anti-IL-23 antibody), along with several combination programs. The company is also exploring indications in rheumatoid arthritis (RA) with SPY002.

The addressable markets for the conditions Spyre Therapeutics is targeting are substantial:

• Inflammatory Bowel Disease (IBD): The global inflammatory bowel disease treatment market was valued at approximately USD 26.55 billion in 2023 and is projected to grow to USD 44.08 billion by 2032. Another estimate puts the global market size at USD 26.6 billion in 2024, expected to reach USD 47.3 billion in 2034. The North American market for IBD treatment was valued at USD 10.89 billion in 2023.
• Atopic Dermatitis: The global atopic dermatitis market size was valued at USD 6.14 billion in 2024 and is projected to reach around USD 12.97 billion by 2034. Other sources indicate the global atopic dermatitis drugs market size was estimated at USD 17.64 billion in 2024 and is projected to reach USD 29.88 billion by 2030. The global atopic dermatitis treatment market was also valued at USD 17.05 billion in 2024 and is expected to reach USD 32.04 billion by 2032.
• Asthma: The global asthma treatment market size is projected to grow from USD 28.55 billion in 2025 to USD 38.57 billion by 2034. Another report estimates the global asthma drugs market size at USD 26.49 billion in 2025 and forecasts it to reach around USD 41.04 billion by 2034. The global asthma therapeutics market was valued at around USD 25.7 billion in 2023.

Spyre Therapeutics (SYRE), a clinical-stage biotechnology company, anticipates several key drivers for future revenue growth over the next 2-3 years, primarily through the advancement and potential commercialization of its pipeline. As the company currently generates no meaningful revenue, these drivers are centered on successful clinical development and market expansion.

• Advancement of Lead Inflammatory Bowel Disease (IBD) Product Candidates: Spyre is progressing its pipeline of extended half-life antibodies, including SPY001 (targeting α4β7), SPY002 (targeting TL1A), and SPY003 (targeting IL-23), for the treatment of IBD. The company expects to deliver multiple Phase 2 proof-of-concept readouts in 2026 from its SKYLINE-UC platform trial in ulcerative colitis, which will assess these monotherapies and their combinations. Positive clinical data will be crucial for advancing these programs and unlocking future revenue potential.
• Successful Development and Market Penetration of Combination Therapies for IBD: Spyre is actively exploring rational combinations of its proprietary antibodies, such as SPY120, SPY130, and SPY230, in IBD. The goal is to achieve best-in-class efficacy with infrequent dosing, and a Phase 2 clinical trial evaluating these combinations is expected to be initiated. Demonstrating superior efficacy with these combinations could significantly differentiate Spyre's offerings and drive substantial market adoption.
• Expansion into New Therapeutic Areas, Particularly Rheumatic Diseases: Spyre is expanding its therapeutic focus beyond IBD into other immune-mediated diseases. Notably, the company initiated the Phase 2 SKYWAY-RD basket trial for SPY072 (an anti-TL1A antibody, also referred to as SPY002) in mid-2025, evaluating its potential in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), with topline results anticipated in 2026. Success in these large rheumatic disease markets would represent a significant expansion of potential revenue streams.
• Differentiation Through Extended Half-Life and Convenient Dosing: A core component of Spyre's strategy is developing antibodies with extended half-lives that allow for less frequent, subcutaneous dosing (e.g., quarterly or twice-annual). This improved patient convenience and adherence, coupled with the potential for superior efficacy, could provide a significant competitive advantage and drive market share upon the eventual commercial launch of its products.

Share Issuance

• In June 2023, in conjunction with its reverse merger with privately held Spyre Therapeutics, Aeglea BioTherapeutics issued approximately 13 million common shares and 365,000 shares of Series A preferred stock to former Spyre security holders.
• In October 2025, Spyre Therapeutics completed an underwritten public offering of 17,094,594 shares of common stock at $18.50 per share, generating approximately $316.2 million in gross proceeds.

Inbound Investments

• In June 2023, concurrent with the acquisition of privately held Spyre Therapeutics, Aeglea BioTherapeutics secured $210 million through a private placement (PIPE) from existing and new investors. This investment was anticipated to fund the company's operations into 2026.